Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected.
Nitric oxide is an important molecule playing a key role in a broad range of biological process such as neurotransmission, vasodilatation and immune responses. While the anti-microbiological properties of nitric oxide-derived reactive nitrogen intermediates (RNI) such as peroxynitrite, are known, the mechanism of these effects are as yet poorly studied. Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) belongs to the family Coronaviridae, was first identified during 2002-2003. Mortality in SARS patients ranges from between 6 to 55%. We have previously shown that nitric oxide inhibits the replication cycle of SARS-CoV in vitro by an unknown mechanism. In this study, we have further investigated the mechanism of the inhibition process of nitric oxide against SARS-CoV. We found that peroxynitrite, an intermediate product of nitric oxide in solution formed by the reaction of NO with superoxide, has no effect on the replication cycle of SARS-CoV, suggesting that the inhibition is either directly effected by NO or a derivative other than peroxynitrite. Most interestingly, we found that NO inhibits the replication of SARS-CoV by two distinct mechanisms. Firstly, NO or its derivatives cause a reduction in the palmitoylation of nascently expressed spike (S) protein which affects the fusion between the S protein and its cognate receptor, angiotensin converting enzyme 2. Secondly, NO or its derivatives cause a reduction in viral RNA production in the early steps of viral replication, and this could possibly be due to an effect on one or both of the cysteine proteases encoded in Orf1a of SARS-CoV.
Centre for Microbiological Preparedness, Swedish Institute for Infectious Disease Control, Nobels Väg 18, Solna, Sweden.
Sara
S
Akerström
Vithiagaran
V
Gunalan
Choong Tat
CT
Keng
Yee-Joo
YJ
Tan
Ali
A
Mirazimi
D000818:Animals; D002522:Chlorocebus aethiops; D006801:Humans; D054878:Lipoylation; D008562:Membrane Glycoproteins / Q000378:metabolism*; D009569:Nitric Oxide / Q000494:pharmacology*; D030421:Peroxynitrous Acid / Q000494:pharmacology; D012367:RNA, Viral / Q000096:biosynthesis* / Q000187:drug effects; D045473:Severe acute respiratory syndrome-related coronavirus / Q000187:drug effects / Q000502:physiology*; D064370:Spike Glycoprotein, Coronavirus; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000378:metabolism*; D014779:Virus Replication
D008562:Membrane Glycoproteins; D012367:RNA, Viral; D064370:Spike Glycoprotein, Coronavirus; D014759:Viral Envelope Proteins; C578557:spike glycoprotein, SARS-CoV; C578553:spike protein, mouse hepatitis virus; D030421:Peroxynitrous Acid; D009569:Nitric Oxide